Idarucizumab Achieves Complete Dabigatran Reversal in Emergency Cohort

Full RE-VERSE AD cohort confirms rapid, durable dabigatran reversal for anticoagulation pharmacists managing life-threatening bleeding or urgent surgery.

idarucizumabdabigatrandirect thrombin inhibitoranticoagulation reversalRE-VERSE ADmajor bleedingatrial fibrillationintracranial hemorrhageNOACDOACsingle-cohort study Cardiology / Anticoagulation

Background Information

Idarucizumab achieves full reversal of dabigatran in emergencies.

Dabigatran requires a reversal agent in cases of uncontrolled bleeding or urgent procedures, and idarucizumab offers this solution. Idarucizumab provided 100% reversal of dabigatran's anticoagulant effect, with bleeding cessation in 2.5 hours and procedure initiation in 1.6 hours. This study provides strong evidence for using idarucizumab in urgent settings, although thrombotic events were noted in 6.3% to 7.4% of patients. Idarucizumab effectively reverses dabigatran in emergencies, facilitating quick intervention.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Citation: Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. The New England journal of medicine. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Full deep analysis for this article is still in progress. Check back soon.